PHIO: Phio Pharmaceuticals Corp Debt to Equity

Phio Pharmaceuticals (PHIO) is developing RNA therapies to combat cancer, utilizing a production outsourcing model to maximize profits. The business is largely decoupled from broader economic trends, relying instead on the success of clinical trials. This chart of the company's market valuation shows a total debt-to-equity ratio of 0.00. The firm's strategy is based on suppressing genes that block the immune response, paving the way for innovative tumor treatment.

Investors are assessing the financial stability of Phio Pharmaceuticals (PHIO) through the total liabilities-to-equity ratio, which determines the business's reliance on external borrowing. By analyzing the leverage of the equity, it can be confirmed that the absence of debt offsets the risks of high cash burn associated with the development of RNA platforms, providing the company with the necessary margin of safety during costly clinical trials.